EAU–ESTRO–SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

https://www.europeanurology.com/article/S0302-2838(13)01040-3/pdf/eau-guidelines-on-prostate-cancer-part-1-screening-diagnosis-and-local-treatment-with-curative-intent-update-2013

EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013

Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions in the breast ducts. The goal for management of DCIS is to prevent the development of invasive breast cancer. This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.

https://www.unitypoint.org/desmoines/filesimages/Cancer%20Education/Oncology%20Nursing%20Conference/2015/2014%20NCCN%20Clin%20Pract%20Guidelines%20Male%20Sex%20Dysf.pdf

Clinical practice guidelines in oncology

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

https://uroweb.org/wp-content/uploads/Heidenreich-A-et-al-Actas-Urol-Esp-2011-359501-EAU-guidelines-on-prostate-cancer.-Part-I.pdf

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Background The combination of radiotherapy plus long-term medical suppression of androgens (≥2 years) improves overall survival in patients with locally advanced prostate cancer We compared the use of radiotherapy plus short-term androgen suppression with the use of radiotherapy plus long-term androgen suppression in the treatment of locally advanced prostate cancer Methods We randomly assigned patients with locally advanced prostate cancer who had received external-beam radiotherapy plus 6 months of androgen suppression to two groups, one to receive no further treatment (short-term suppression) and the other to receive 25 years of further treatment with a luteinizing hormone–releasing hormone agonist (long-term suppression) An outcome of noninferiority of short-term androgen suppression as compared with long-term suppression required a hazard ratio of more than 135 for overall survival, with a one-sided alpha level of 005 An interim analysis showed futility, and the results are presented with an a

https://www.nejm.org/doi/pdf/10.1056/NEJMoa0810095

Elsbietha M. van der Steen-Banasik

Papers

Duration of androgen suppression in the treatment of prostate cancer.